Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators

Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators

To jointly assess the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on cardiorenal outcomes and all-cause mortality in type 2 diabetes mellitus (T2DM) with or at high risk of cardiovascular disease (CVD). We performed a systematic review and network meta-analysis, sy...

Full description

Bibliographic Details
Main Authors:	Vicente Martínez-Vizcaíno, Ana Díez-Fernández, Celia Álvarez-Bueno, Julia Martínez-Alfonso, Iván Cavero-Redondo
Format:	Article
Language:	English
Published:	MDPI AG 2021-06-01
Series:	Journal of Clinical Medicine
Subjects:	sodium-glucose cotransporter 2 inhibitors meta-analysis efficacy adverse effects cardiovascular disease mortality
Online Access:	https://www.mdpi.com/2077-0383/10/12/2713

Similar Items

Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
by: Rosalba La Grotta, et al.
Published: (2022-10-01)

SGLT2 Inhibitors as Potential Anticancer Agents
by: Debasish Basak, et al.
Published: (2023-06-01)

Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
by: Caiyun Zheng, et al.
Published: (2021-04-01)

Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence
by: Pieter Evenepoel, et al.
Published: (2022-03-01)

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
by: Keming Huang, et al.
Published: (2023-04-01)

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
by: Yoshifumi Saisho
Published: (2020-05-01)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
by: Bonora BM, et al.
Published: (2020-01-01)

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
by: David Bobrowski, et al.
Published: (2021-11-01)

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
by: Yao Hao Teo, et al.
Published: (2021-03-01)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
by: Xiutian Chen, et al.
Published: (2023-11-01)

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
by: Lisanne C. A. Smidt, et al.
Published: (2021-09-01)

Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
by: Peipei Zhou, et al.
Published: (2023-03-01)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
by: Annamaria Mascolo, et al.
Published: (2022-09-01)

SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes
by: Natalia Stepanova
Published: (2024-01-01)

Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how? A narrative literature review
by: Henri Lu, et al.
Published: (2020-09-01)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
by: Jimmy Gonzalez, et al.
Published: (2023-03-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

SGLT2 inhibitor versus carbohydrate-restricted isocaloric diet: reprogramming substrate oxidation in type 2 diabetes
by: Hiroyuki Igarashi, et al.
Published: (2023-02-01)

Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells
by: Dan Nakano, et al.
Published: (2022-04-01)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01)

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
by: Ellen Vercalsteren, et al.
Published: (2024-02-01)

Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review
by: Hammad Rahman, et al.
Published: (2023-08-01)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
by: Weronika Frąk, et al.
Published: (2023-07-01)

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
by: Minji Sohn, et al.
Published: (2023-06-01)

SGLT2-Inhibitors and Euglycemia Diabetic Ketoacidosis: A Missed Diagnosis
by: Muhammad Nadeem Ahmed Khan, et al.
Published: (2023-12-01)

Direct cardiac effects of SGLT2 inhibitors
by: Sha Chen, et al.
Published: (2022-03-01)

Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
by: Habib Yaribeygi, et al.
Published: (2022-11-01)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01)

Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
by: Takeshi Horii, et al.
Published: (2023-11-01)

Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model
by: Chang Chu, et al.
Published: (2022-09-01)

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
by: Yan-Rong Li, et al.
Published: (2021-08-01)

Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study
by: Lauren K. Park, et al.
Published: (2023-05-01)

The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis
by: Chunmei Xu, et al.
Published: (2022-10-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019-08-01)

Neuroprotective Effect of SGLT2 Inhibitors
by: Agnieszka Pawlos, et al.
Published: (2021-11-01)

SGLT2i: beyond the glucose-lowering effect
by: Lihua Ni, et al.
Published: (2020-06-01)

Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials
by: Xi Rong, et al.
Published: (2022-11-01)

The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review
by: Yasunori Miyamoto, et al.
Published: (2023-03-01)

Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
by: Min Sun, et al.
Published: (2024-03-01)

Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study
by: Carlos King Ho Wong, et al.
Published: (2022-06-01)